CEbiotech.com - Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Most popular
searches

All articles

Filters:
Show search box
2013-11-12
Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Merck, one of the leaders in production of pharmaceuticals, put its new medicine under review. It is called vintafolide, MK-8109 and it is an injectable drug conjugate consisting of folate (vitamin B9) linked to alkaloid chemotherapy agent, desacetylvinblastine monohydrazine (DAVLBH). ... Read more
Tags medicine , cancer , Merck , MSD , cancer targetting